Anadis clinical trial gets go-ahead

By Dylan Bushell-Embling
Wednesday, 03 September, 2008

The Israeli Ministry of Health has approved Anadis' (ASX:ANX) clinical protocol, clearing the way for trials of its mucositis treatment to begin within a month.

Mucostisis is a significant side effect of cancer therapy, experienced by between 20 and 100 per cent of patients, depending on the type of cancer and treatment.

Effects include painful mouth ulcerations and severe gastrointestinal symptoms.

The Anadis drug contains a unique formulation of Anadis' immune milk-derived anti LPS antibodies as well as other bioactives, and will be delivered using Anadis' oral delivery technology.

Anadis was recently awarded a grant from Vistech to help fund the drug development program.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd